As the aesthetic medicine landscape shifts from volumization toward genuine tissue regeneration, a new class of biomaterials is emerging. Medifab (메디팹) has developed three proprietary platform technologies that address longstanding limitations of conventional fillers and skin boosters — most notably the poor water solubility of chitosan and the immunogenic risks of ECM-derived materials. Here is a closer look at each platform.
Water-Soluble Chitosan Platform
CHITOGEN™
Chitosan has long been recognized for its anti-inflammatory, antibacterial, and tissue-regenerating properties. However, its naturally low water solubility had been a persistent barrier to practical medical application — until now.
- Produces high-purity, water-soluble chitosan suitable for medical-grade applications through a proprietary processing technique
- Incorporates LTG (Liquid-to-Gel) technology — the material transitions from liquid to gel upon injection into the body, improving delivery precision and in-situ retention
- Adaptable to both injectable and topical formulations, allowing expansion across multiple product categories from skin boosters to dermal fillers
Clinical relevance: The LTG phase-transition behavior means the formulation remains easy to inject with low viscosity, then gels in situ to provide structural support and prolonged bioactive contact — addressing a key limitation of conventional aqueous injectables.
dECM Regenerative Signaling Platform
REGENTRIX™
A world-first platform based on decellularized extracellular matrix (dECM). Rather than simply filling tissue, REGENTRIX™ is designed to restore the biological environment that enables cells to repair themselves.
- Utilizes supercritical CO₂ (scCO₂) processing to selectively eliminate immunogenic components while preserving key regenerative signals — collagen, elastin, and endogenous growth factors
- Delivers biological cues that activate cellular self-repair and regeneration, rather than relying solely on exogenous volume replacement
- Active ingredient formally registered in the ICID (International Cosmetic Ingredient Dictionary), supporting global regulatory submissions
Why supercritical CO₂? Unlike conventional decellularization methods (detergent-based or enzymatic), scCO₂ processing operates without harsh chemicals, reducing residual cytotoxicity while more faithfully preserving the native ECM architecture — including its nano-scale fibrous structure that guides cell migration and adhesion.
Next-Generation Convergence Platform
CHITOGENIX™
CHITOGENIX™ represents the convergence of CHITOGEN™ and REGENTRIX™ into a unified advanced platform — combining the structural and anti-inflammatory benefits of water-soluble chitosan with the regenerative signaling capacity of dECM.
- Functions as a biomimetic regenerative system, closely replicating the body's natural tissue repair cascade at the molecular level
- Engineered for broad tissue applicability: skin, scalp, cartilage, and musculoskeletal structures — all addressable from a single platform
- Efficacy scientifically validated through collaborative research with KIST (Korea Institute of Science and Technology)
- Key findings published in Advanced Healthcare Materials (SCI-indexed, IF = 10), co-authored with the Department of Plastic Surgery, Seoul National University College of Medicine
- Research recognized by Hanbitsa — Korea's distinguished scientists recognition list
Broader implications: By combining chitosan's scaffolding and antimicrobial properties with dECM-derived regenerative signals, CHITOGENIX™ moves beyond conventional aesthetic indications. Current R&D pipelines include next-generation skin boosters, hair follicle regeneration, and — in partnership with Seoul National University Hospital — an injectable platform for degenerative osteoarthritis, targeting IND filing within 1–2 years.